{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:40:23Z","timestamp":1792478423797,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by Department of Science and Technology funding through the \u201cPromotion of University Research and Scientific Excellence\u201d (PURSE) scheme","award":["Sanction number: SR\/PURSE\/2021\/81 (G)."],"award-info":[{"award-number":["Sanction number: SR\/PURSE\/2021\/81 (G)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03452-x","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:22:39Z","timestamp":1792470159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5879-7479","authenticated-orcid":false,"given":"Varshini","family":"Manjunath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0485-7581","authenticated-orcid":false,"given":"Rachana Rajesh","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4580-8209","authenticated-orcid":false,"given":"Ananth Koushik","family":"Bhujanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-5918","authenticated-orcid":false,"given":"Arpitha Maraliga","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-375X","authenticated-orcid":false,"given":"Prasanna Kumar","family":"Santhekadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"3452_CR1","first-page":"6","volume":"8","author":"MR Ataollahi","year":"2015","unstructured":"Ataollahi MR, Sharifi J, Paknahad MR, Paknahad A. Breast cancer and associated factors: a review. J Med Life. 2015;8:6. (Spec Iss 4).","journal-title":"J Med Life"},{"issue":"12","key":"3452_CR2","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2217\/14622416.9.12.1879","volume":"9","author":"PK Lo","year":"2008","unstructured":"Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics. 2008;9(12):1879\u2013902.","journal-title":"Pharmacogenomics"},{"issue":"12","key":"3452_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(04)01653-5","volume":"5","author":"DL Ellsworth","year":"2004","unstructured":"Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol. 2004;5(12):753\u20138.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3452_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","volume":"2","author":"TJ Key","year":"2001","unstructured":"Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133\u201340.","journal-title":"Lancet Oncol"},{"key":"3452_CR5","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. Subtypes of breast cancer. In: Mayrovitz HN. editor. Breast Cancer. Brisbane (AU): Exon Publications.[Internet]. 2022.31-42","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"7","key":"3452_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3452_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3452_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163(1):39\u201353.","journal-title":"Cell"},{"issue":"11","key":"3452_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson B, Li Y, Lin Y, Liu ET, Patnai A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8(11):1358.","journal-title":"Cancer Discov"},{"issue":"6","key":"3452_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/014107689408700603","volume":"87","author":"JL Turk","year":"1994","unstructured":"Turk JL. Paul Ehrlich-the dawn of immunology. J R Soc Med. 1994;87(6):314\u20135.","journal-title":"J R Soc Med"},{"issue":"2","key":"3452_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000443526","volume":"8","author":"P Valent","year":"2016","unstructured":"Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, Smolen JS. Paul Ehrlich (1854\u20131915) and his contributions to the foundation and birth of translational medicine. J Innate Immun. 2016;8(2):111\u201320.","journal-title":"J Innate Immun"},{"issue":"6","key":"3452_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/sti.59.6.404","volume":"59","author":"AL Thorburn","year":"1983","unstructured":"Thorburn AL. Paul Ehrlich: pioneer of chemotherapy and cure by arsenic (1854\u20131915). Sex Transm Infect. 1983;59(6):404\u20135.","journal-title":"Sex Transm Infect"},{"issue":"8","key":"3452_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1309\/LMHJS86N5ICBIBWM","volume":"41","author":"M Titford","year":"2010","unstructured":"Titford M. Paul Ehrlich: Histological staining, immunology, chemotherapy. Lab Med. 2010;41(8):497\u20138.","journal-title":"Lab Med"},{"issue":"3","key":"3452_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jinf.2004.05.022","volume":"54","author":"GF Gensini","year":"2007","unstructured":"Gensini GF, Conti AA, Lippi D. The contributions of Paul Ehrlich to infectious disease. J Infect. 2007;54(3):221\u20134.","journal-title":"J Infect"},{"issue":"8","key":"3452_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.micinf.2004.04.003","volume":"6","author":"F Winau","year":"2004","unstructured":"Winau F, Westphal O, Winau R. Paul Ehrlich\u2014in search of the magic bullet. Microbes Infect. 2004;6(8):786\u20139.","journal-title":"Microbes Infect"},{"issue":"13","key":"3452_CR16","first-page":"2375","volume":"10","author":"M Ozaslan","year":"2011","unstructured":"Ozaslan M, Karagoz ID, Kilic IH, Guldur ME. Ehrlich ascites carcinoma. Afr J Biotechnol. 2011;10(13):2375\u20138.","journal-title":"Afr J Biotechnol"},{"key":"3452_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/tbcr-23-32","volume":"4","author":"DR Radulski","year":"2023","unstructured":"Radulski DR, Stipp MC, Galindo CM, Acco A. Features and applications of Ehrlich tumor model in cancer studies: a literature review. Translational Breast Cancer Res. 2023;4:22.","journal-title":"Translational Breast Cancer Res"},{"key":"3452_CR18","doi-asserted-by":"publisher","first-page":"118578","DOI":"10.1016\/j.lfs.2020.118578","volume":"264","author":"IB Feitosa","year":"2021","unstructured":"Feitosa IB, Mori B, Teles CB, da Costa AG. What are the immune responses during the growth of Ehrlich\u2019s tumor in ascitic and solid form? Life Sci. 2021;264:118578.","journal-title":"Life Sci"},{"issue":"1","key":"3452_CR19","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1038\/s41598-018-23669-9","volume":"8","author":"S Mishra","year":"2018","unstructured":"Mishra S, Tamta AK, Sarikhani M, Desingu PA, Kizkekra SM, Pandit AS, Kumar S, Khan D, Raghavan SC, Sundaresan NR. Subcutaneous Ehrlich Ascites Carcinoma mice model for studying cancer-induced cardiomyopathy. Sci Rep. 2018;8(1):5599.","journal-title":"Sci Rep"},{"key":"3452_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lfs.2016.08.009","volume":"162","author":"FT Frajacomo","year":"2016","unstructured":"Frajacomo FT, de Souza Padilha C, Marinello PC, Guarnier FA, Cecchini R, Duarte JA, Deminice R. Solid Ehrlich carcinoma reproduces functional and biological characteristics of cancer cachexia. Life Sci. 2016;162:47\u201353.","journal-title":"Life Sci"},{"key":"3452_CR21","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.adcanc.2022.100029","volume":"4","author":"NG Gowda","year":"2022","unstructured":"Gowda NG, Shiragannavar VD, Prabhuswamimath SC, Tuladhar S, Chidambaram SB, Santhekadur PK. Ehrlich Ascites carcinoma mice model for studying liver inflammation and fibrosis. Adv Cancer Biology-Metastasis. 2022;4:100029.","journal-title":"Adv Cancer Biology-Metastasis"},{"issue":"5","key":"3452_CR22","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731\u20138.","journal-title":"J Immunol"},{"issue":"9","key":"3452_CR23","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"110","author":"J Seok","year":"2013","unstructured":"Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci. 2013;110(9):3507\u201312.","journal-title":"Proc Natl Acad Sci"},{"issue":"2\u20133","key":"3452_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1242\/dmm.000976","volume":"1","author":"A Richmond","year":"2008","unstructured":"Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Models Mech. 2008;1(2\u20133):78\u201382.","journal-title":"Dis Models Mech"},{"issue":"18","key":"3452_CR25","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"issue":"7","key":"3452_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/138920210793175895","volume":"11","author":"LA MacFarlane","year":"2010","unstructured":"MacFarlane LA, Murphy R. MicroRNA: biogenesis, function and role in cancer. Curr Genom. 2010;11(7):537\u201361.","journal-title":"Curr Genom"},{"issue":"5","key":"3452_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1535370220907314","volume":"245","author":"PS Chen","year":"2020","unstructured":"Chen PS, Lin SC, Tsai SJ. Complexity in regulating microRNA biogenesis in cancer. Experimental Biology Med. 2020;245(5):395\u2013401.","journal-title":"Experimental Biology Med"},{"issue":"2","key":"3452_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"issue":"8","key":"3452_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3452_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s43556-025-00261-y","volume":"6","author":"X Dai","year":"2025","unstructured":"Dai X, Xi M, Li J. Cancer metastasis: molecular mechanisms and therapeutic interventions. Mol Biomed. 2025;6(1):20.","journal-title":"Mol Biomed"},{"issue":"10","key":"3452_CR31","doi-asserted-by":"publisher","first-page":"101042831769593","DOI":"10.1177\/1010428317695933","volume":"39","author":"F Mello-Andrade","year":"2017","unstructured":"Mello-Andrade F, da Costa WL, Pires WC, Pereira FD, Cardoso CG, Lino-Junior RD, Irusta VR, Carneiro CC, de Melo-Reis PR, Castro CH, Almeida MA. Antitumor effectiveness and mechanism of action of Ru (II)\/amino acid\/diphosphine complexes in the peritoneal carcinomatosis progression. Tumor Biology. 2017;39(10):1010428317695933.","journal-title":"Tumor Biology"},{"issue":"1","key":"3452_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.32604\/or.2023.042350","volume":"32","author":"S Yilmaz","year":"2023","unstructured":"Yilmaz S, Do\u011fanyi\u011fit Z\u00dc, Ocak M, S\u00f6ylemez ES, Oflamaz AO, U\u00e7ar S, Ate\u015f \u015e, Farooqi AA. Inhibition of Ehrlich ascites carcinoma growth by melatonin: Studies with micro-CT. Oncol Res. 2023;32(1):175.","journal-title":"Oncol Res"},{"key":"3452_CR33","first-page":"1","volume":"9","author":"WA El-Dakroury","year":"2025","unstructured":"El-Dakroury WA, Zewail MB, Mansour MA, Mohammed OA, Doghish AS, Senbel A, Sallam AA, Gebril MI, Abouzid KA, Noshy M, Nomier YA. A novel furo [2, 3-d] pyrimidine-based chalcone derivative (MMK-1931) loaded chitosomes as a potential cancer therapy in an Ehrlich ascites tumor model. J Drug Target. 2025;9:1\u20138.","journal-title":"J Drug Target"},{"issue":"12","key":"3452_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc.2016.91","volume":"16","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel L, Pitt JM, Daill\u00e8re R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16(12):759\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3452_CR35","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1186\/s12885-025-15279-2","volume":"25","author":"AN Alshammari","year":"2025","unstructured":"Alshammari AN, Alfawaz MS, Alenezi YM, Al-Ghafari AB, Al Doghaither HA, Elmorsy EM, Atta MM, El-Raghi AA. Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model. BMC Cancer. 2025;25(1):1838.","journal-title":"BMC Cancer"},{"issue":"1","key":"3452_CR36","doi-asserted-by":"publisher","first-page":"42910","DOI":"10.1038\/s41598-025-27352-8","volume":"15","author":"MT Mansour","year":"2025","unstructured":"Mansour MT, Hussein MA, Emara AA, El-Sherif RM. Ferulic acid-loaded chitosan nanoparticles enhance radiotherapy efficacy via STAT3 suppression and caspase-8\/p53 activation in Ehrlich ascites carcinoma. Sci Rep. 2025;15(1):42910.","journal-title":"Sci Rep"},{"issue":"1","key":"3452_CR37","doi-asserted-by":"publisher","first-page":"20319","DOI":"10.1038\/s41598-025-02442-9","volume":"15","author":"N Saleh","year":"2025","unstructured":"Saleh N, Allam T, Korany RM, Abdelfattah AM, Omran AM, Attia Abd Eldaim M. Borai El-Borai N. Hesperidin exacerbates the therapeutic potency of cisplatin against hepatocytotoxicity of Ehrlich ascites carcinoma in mice. Sci Rep. 2025;15(1):20319.","journal-title":"Sci Rep"},{"issue":"12","key":"3452_CR38","doi-asserted-by":"publisher","first-page":"e22924","DOI":"10.1002\/jbt.22924","volume":"35","author":"HH Atteia","year":"2021","unstructured":"Atteia HH, Arafa MH, Mohammad NS, Amin DM, Sakr AT. Thymoquinone upregulates miR-125a\u20105p, attenuates STAT3 activation, and potentiates doxorubicin antitumor activity in murine solid Ehrlich carcinoma. J Biochem Mol Toxicol. 2021;35(12):e22924.","journal-title":"J Biochem Mol Toxicol"},{"issue":"7","key":"3452_CR39","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/molecules29071614","volume":"29","author":"Y Elmahboub","year":"2024","unstructured":"Elmahboub Y, Albash R, Magdy William M, Rayan AH, Hamed NO, Ousman MS, Raslan NA, Mosallam S. Metformin loaded zein polymeric nanoparticles to augment antitumor activity against ehrlich carcinoma via activation of AMPK pathway: D-optimal design optimization, in vitro characterization, and in vivo study. Molecules. 2024;29(7):1614.","journal-title":"Molecules"},{"issue":"1","key":"3452_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","volume":"18","author":"Y Hasin","year":"2017","unstructured":"Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.","journal-title":"Genome Biol"},{"issue":"10","key":"3452_CR41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113\u201320.","journal-title":"Nat Genet"},{"issue":"4","key":"3452_CR42","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","volume":"177","author":"S Vasaikar","year":"2019","unstructured":"Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177(4):1035\u201349.","journal-title":"Cell"},{"key":"3452_CR43","doi-asserted-by":"publisher","first-page":"730240","DOI":"10.3389\/fcell.2021.730240","volume":"9","author":"Y Lu","year":"2021","unstructured":"Lu Y, Jin J, Du Q, Hu M, Wei Y, Wang M, Li H, Li Q. Multi-omics analysis of the anti-tumor synergistic mechanism and potential application of immune checkpoint blockade combined with lenvatinib. Front Cell Dev Biology. 2021;9:730240.","journal-title":"Front Cell Dev Biology"},{"issue":"4","key":"3452_CR44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683\u201392.","journal-title":"Cell"},{"issue":"1","key":"3452_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327.","journal-title":"Cell"},{"issue":"6348","key":"3452_CR46","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357(6348):eaal2380.","journal-title":"Science"},{"issue":"1","key":"3452_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","volume":"18","author":"E Papalexi","year":"2018","unstructured":"Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18(1):35\u201345.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3452_CR48","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang SR, Kurian A, Van Valen D, West R, Bendall SC. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373\u201387.","journal-title":"Cell"},{"issue":"9","key":"3452_CR49","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N, Wang T. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53(9):1334\u201347.","journal-title":"Nat Genet"},{"issue":"10","key":"3452_CR50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41576-021-00370-8","volume":"22","author":"SK Longo","year":"2021","unstructured":"Longo SK, Guo MG, Ji AL, Khavari PA. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. Nat Rev Genet. 2021;22(10):627\u201344.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"3452_CR51","doi-asserted-by":"publisher","first-page":"e00770","DOI":"10.1002\/smtd.202500770","volume":"9","author":"D Liu","year":"2025","unstructured":"Liu D, Xiao L, Wu Y, Yue C, Li M, Sun Y, Yang C. Spatially Resolved Transcriptomics: Revealing Tumor Microenvironment Heterogeneity to Advance Cancer Immunotherapy. Small Methods. 2025;9(11):e00770.","journal-title":"Small Methods"},{"issue":"2","key":"3452_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrg.2017.97","volume":"19","author":"JG Doench","year":"2018","unstructured":"Doench JG. Am I ready for CRISPR? A user\u2019s guide to genetic screens. Nat Rev Genet. 2018;19(2):67\u201380.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"3452_CR53","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, Sullender ME, Vaimberg EW, Goodale A, Root DE, Piccioni F, Doench JG. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018;9(1):5416.","journal-title":"Nat Commun"},{"issue":"4","key":"3452_CR54","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/nar\/gkad046","volume":"51","author":"M Dede","year":"2023","unstructured":"Dede M, Hart T. Recovering false negatives in CRISPR fitness screens with JLOE. Nucleic Acids Res. 2023;51(4):1637\u201351.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3452_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"issue":"6382","key":"3452_CR56","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"1","key":"3452_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380.","journal-title":"Cell"},{"issue":"2","key":"3452_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumor heterogeneity and resistance to cancer therapies. Nat reviews Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat reviews Clin Oncol"},{"key":"3452_CR59","unstructured":"Seyhan AA. Lost in Translation\u2013Crossing the Valley of Death across preclinical and clinical divide."},{"key":"3452_CR60","doi-asserted-by":"crossref","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research.PLoS biology. 2020 Jul 14;18(7):e3000410.","DOI":"10.1371\/journal.pbio.3000410"},{"issue":"2","key":"3452_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1242\/dmm.024547","volume":"9","author":"MJ Justice","year":"2016","unstructured":"Justice MJ, Dhillon P. Using the mouse to model human disease: increasing validity and reproducibility. Dis Models Mech. 2016;9(2):101\u20133.","journal-title":"Dis Models Mech"},{"issue":"6","key":"3452_CR62","doi-asserted-by":"publisher","first-page":"e1002165","DOI":"10.1371\/journal.pbio.1002165","volume":"13","author":"LP Freedman","year":"2015","unstructured":"Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol. 2015;13(6):e1002165.","journal-title":"PLoS Biol"},{"issue":"6382","key":"3452_CR63","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366\u201370.","journal-title":"Science"},{"issue":"6371","key":"3452_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP. Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"6371","key":"3452_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daill\u00e8re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"4","key":"3452_CR66","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657\u201369.","journal-title":"Cell"},{"issue":"9","key":"3452_CR67","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3452_CR68","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.","journal-title":"Sci Adv"},{"issue":"3","key":"3452_CR69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41568-019-0237-2","volume":"20","author":"AH Zahalka","year":"2020","unstructured":"Zahalka AH, Frenette PS. Nerves in cancer. Nat Rev Cancer. 2020;20(3):143\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"3452_CR70","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.neuron.2025.08.015","volume":"113","author":"G Jones","year":"2025","unstructured":"Jones G, Anderson JL, Nguyen PT, Gleber-Netto FO, Hwang WL, Puduvalli VK, Monje M, Amit M. Novel approaches to clinical trial design in cancer neuroscience. Neuron. 2025;113(17):2791\u2013813.","journal-title":"Neuron"},{"issue":"8","key":"3452_CR71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MT, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends cancer. 2019;5(8):475\u201394.","journal-title":"Trends cancer"},{"issue":"15","key":"3452_CR72","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1158\/0008-5472.CAN-19-0566","volume":"79","author":"AA Shafi","year":"2019","unstructured":"Shafi AA, Knudsen KE. Cancer and the circadian clock. Cancer Res. 2019;79(15):3806\u201314.","journal-title":"Cancer Res"},{"issue":"2","key":"3452_CR73","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cmet.2016.07.001","volume":"24","author":"T Papagiannakopoulos","year":"2016","unstructured":"Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metabol. 2016;24(2):324\u201331.","journal-title":"Cell Metabol"},{"key":"3452_CR74","doi-asserted-by":"publisher","first-page":"1240676","DOI":"10.3389\/fonc.2023.1240676","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, Khan S, Nabi G, Li HY. Circadian rhythm as a key player in cancer progression as well as a therapeutic target in HER2-positive advanced gastric cancer treatment. Front Oncol. 2023;13:1240676.","journal-title":"Front Oncol"},{"issue":"2","key":"3452_CR75","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.gendis.2019.09.009","volume":"7","author":"PK Santhekadur","year":"2020","unstructured":"Santhekadur PK, Kumar DP. RISC assembly and post-transcriptional gene regulation in Hepatocellular Carcinoma. Genes Dis. 2020;7(2):199\u2013204.","journal-title":"Genes Dis"},{"issue":"1","key":"3452_CR76","first-page":"41","volume":"22","author":"LD Puttahanumantharayappa","year":"2023","unstructured":"Puttahanumantharayappa LD, Shiragannavar VD, Sannappa Gowda NG, Karunakara SH, Santhekadur PK. Telomerase, an Accomplice of RNA-induced Silencing Complex in Hepatocellular Carcinoma. Gene Expr. 2023;22(1):41\u20136.","journal-title":"Gene Expr"},{"issue":"2","key":"3452_CR77","doi-asserted-by":"publisher","first-page":"e70068","DOI":"10.1002\/mog2.70068","volume":"5","author":"Z Wang","year":"2026","unstructured":"Wang Z, Li B, Tang P, Yan F, Wang S, Leng G, Dawa P, Chen Y, Guo Y, Yang P, Li Y. Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives. MedComm\u2013Oncology. 2026;5(2):e70068.","journal-title":"MedComm\u2013Oncology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03452-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03452-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03452-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:02:19Z","timestamp":1792476139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03452-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":77,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03452-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"342"}}